FORA Capital’s IGM Biosciences IGMS Stock Holding History

FORA Capital’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,650	Closed	-$234K	–	921
2020 Q4	$234K	Buy	+2,650	New	+$186K	0.04%	479

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FORA Capital's IGMS Position: Q1 2021 in Review

FORA Capital sold out of IGM Biosciences (IGMS) in Q1 2021, closing a stake of 2,650 shares — an estimated $234K sold.

FORA Capital first reported a position in IGMS in Q4 2020 and held it in 1 quarter. The position peaked at $234K in Q4 2020. 109 funds tracked by Wall St. Rank hold IGMS as of Q1 2021.

FORA Capital reported no remaining IGM Biosciences position as of Q1 2021 after selling out during the quarter.
FORA Capital sold 2,650 IGM Biosciences shares in Q1 2021, an estimated $234K.
FORA Capital first reported a position in IGM Biosciences in Q4 2020 and held it in 1 quarter.
FORA Capital's IGM Biosciences position peaked at $234K in Q4 2020.
109 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2021.

Based on FORA Capital's 13F filing for Q1 2021, filed 17 May 2021.